Stock Events

MeiraGTx 

€5.55
0
+€0+0% Thursday 07:11

Statistics

Day High
5.55
Day Low
5.55
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
348.25M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MarExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Next
-0.83
-0.72
-0.6
-0.49
Expected EPS
-0.51
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 328.F. It's not an investment recommendation.

About

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
Show more...
CEO
Dr. Alexandria Forbes Ph.D.
Employees
407
Country
KY
ISIN
KYG596651029
WKN
000A2JGHF

Listings